Oligonucleotide Design Lead
Pubblicato il 02-10-2026 - Grünenthal Group in Origgio
Professional | Permanent | Full-time | Hybrid
Pronto/a a candidarsi? Prima di farlo, si assicuri di leggere tutti i dettagli relativi a questo lavoro nella descrizione sottostante.
If you’re passionate about changing lives for the better, this is the opportunity you’ve been waiting for. In Research & Development, we’re continuously exploring innovative new treatment options to make a stronger, more positive impact on the lives of the patients we serve. You’ll work with talented colleagues in a state-of-the-art Research & Development environment, developing innovative medicines that change the life of patients for the better and help us make progress towards our vision of a world free of pain. Join us today, and discover the difference you can make.
What The Job Looks LikeEvery day you will enjoy different challenges such as:
- Lead the design and computational optimisation of RNA therapeutics, particularly siRNA, integrating RNA biology with oligonucleotide chemistry to enable gene knockdown and RNA regulatory approaches, including up-regulation strategies.
- Define and prioritise target sites and design strategies by integrating sequence features, RNA accessibility, transcript structure, cross-species alignment, and emerging experimental data
- Drive iterative design–test–learn cycles by analysing and rapidly integrating datasets linking sequence, chemistry, and biological activity to inform decision-making
- Develop and apply computational tools and workflows (e.g. Python or R) to enable scalable oligonucleotide design, data integration, and rapid sequence–chemistry iteration
- Partner closely with oligonucleotide chemists and delivery scientists to co-optimise sequence, chemical modifications, and delivery approaches to maximise potency, durability, and tissue activity
- Lead and contribute to discovery programs advancing RNA therapeutic candidates toward candidate profiling and clinical development, while helping prioritise and evaluate new targets aligned with